


CLAIMS

1. Use of a compound of formula (I)



5

(I)

wherein:

R¹ is aryl;

R² is H, alkyl or aryl; and

R³ is hydrogen or alkyl;

10 or a pharmaceutically acceptable salt or prodrug thereof, in the manufacture of a medicament for the treatment of a disorder mediated by CB₁ receptors.

2. A use according to claim 1 wherein R¹ is a substituted or unsubstituted phenyl or naphthyl.

15

3. A use according to claim 1 or 2 wherein R¹ has 1, 2 or 3 substituent groups.

4. A use according to claim 1, 2 or 3 wherein R¹ is chlorophenyl or (trifluoromethyl)phenyl.

20

5. A use according to claim 1, 2, 3 or 4 wherein R² is aryl.

6. A use according to any one of claims 1 to 5 wherein R³ is alkyl.

25 7. A use according to claim 1 wherein the compound is selected from:

3-(bis(4-chlorophenyl)methoxy)-N-(2-propenyl)azetidine-1-carboxamide; and

(R)-3-(bis(4-chlorophenyl)methoxy)-N-(2-hydroxypropyl)azetidine-1-carboxamide.

8. A use according to any preceding claim wherein said medicament comprises a pharmaceutically acceptable carrier and as active ingredient an effective amount of a compound of formula (I).
- 5 9. A method of treatment of a disorder mediated by CB₁ receptors comprising administration to a subject in need of such treatment an effective dose of a compound of formula (I) as defined in any of claims 1 to 8, or a pharmaceutically acceptable salt or prodrug thereof.
- 10 10. A use or method according to any preceding claim wherein the disorder is selected from psychosis, schizophrenia, cognitive disorders, attention deficit disorder, to gastrointestinal disorders, smoking cessation, obesity and other eating disorders associated with excessive food intake, and non-insulin dependant diabetes mellitus.
- 15 11. A use or method according to any of claims 1 to 10 wherein the disorder is obesity.
12. A use or method according to any of claims 1 to 10 for smoking cessation.
13. A use or method according to any of claims 1 to 10 wherein said disorder is a
20 gastrointestinal disorder.